PeptiDream (4587.T)

Executive Summary

PeptiDream is a Tokyo-based biopharmaceutical company that has developed a proprietary Peptide Discovery Platform System (PDPS) for the rapid identification of macrocyclic peptide therapeutics. Unlike traditional biologics or small molecules, macrocyclic peptides can target intracellular protein-protein interactions that are considered undruggable, offering a unique therapeutic modality. The company’s platform combines cell-free translation with mRNA display screening, enabling high-throughput selection of drug-like peptides with high affinity and specificity. PeptiDream has established numerous high-value partnerships with major pharmaceutical companies, including Merck KGaA, Novartis, and Bristol Myers Squibb, leveraging its platform to generate novel drug candidates. These collaborations have provided significant non-dilutive funding and validation, while PeptiDream retains rights to co-develop and share profits on certain programs. The company also maintains an internal pipeline focused on oncology and rare diseases, with several candidates advancing toward clinical proof-of-concept. With a market capitalization over $140 billion, PeptiDream is one of the largest biotech companies globally, reflecting strong investor confidence in its platform and pipeline potential.

Upcoming Catalysts (preview)

• Q3 2026Phase 1/2 data readout for internal oncology candidate (e.g., PDPS-targeted degraders)60% success
• Q4 2026Merck KGaA opt-in decision on partnered programs under the 2022 license agreement50% success
• Q2 2026New major partnership announcement with a top pharmaceutical company70% success